<SEC-DOCUMENT>0001193125-12-360928.txt : 20120817
<SEC-HEADER>0001193125-12-360928.hdr.sgml : 20120817
<ACCEPTANCE-DATETIME>20120817171823
ACCESSION NUMBER:		0001193125-12-360928
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120815
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120817
DATE AS OF CHANGE:		20120817

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		121043297

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d399852d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): August&nbsp;17, 2012 (August 15, 2012) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;16, 2012, ARCA issued a press release announcing that its Chairman
Richard B. Brewer had died on August&nbsp;15, 2012. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial
Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;ARCA ANNOUNCES DEATH OF BOARD CHAIR RICHARD B. BREWER, TRAILBLAZING BIOTECHNOLOGY INDUSTRY VETERAN AND PATIENT ADVOCATE,&#148; dated August 16,
2012.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: August&nbsp;17, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title: SVP &amp; General Counsel</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d399852dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g399852g13w95.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Derek Cole </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Investor Relations&nbsp;&amp; Corporate Communications </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2163 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA ANNOUNCES DEATH OF BOARD CHAIR RICHARD B. BREWER, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TRAILBLAZING
BIOTECHNOLOGY INDUSTRY VETERAN AND PATIENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADVOCATE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, August&nbsp;16, 2012</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that Richard B. Brewer, 61, Chairman of its Board of Directors, has died after a long battle with
multiple myeloma, a type of blood cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Dick will be sorely missed by his family, friends, colleagues, and patients whose lives were
impacted by the tremendous contributions he made to the biotechnology industry in his illustrious career and life well lived,&#148; commented Michael Bristow, MD, PhD, President and CEO of ARCA biopharma. &#147;He was truly one of a kind.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Brewer spent nearly 35 years in the biotech and pharmaceutical industries guiding development and commercialization of such breakthrough
drugs as human growth hormone for children&#146;s growth disorders; the first new drug in 30 years for cystic fibrosis; the first new drug in over a decade for heart failure; pioneering clot-busting drugs for heart attacks and strokes; and other
first-in-class drugs and devices for cancer and heart disease. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product
candidate, Gencaro</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the
potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with the Laboratory Corporation of America (LabCorp), under which LabCorp has developed a companion genetic test for Gencaro. For more
information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release and the associated presentation may contain &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation
prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with:
the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; the protection and market exclusivity provided by the Company&#146;s intellectual property; risks
related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including
without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2011 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g399852g13w95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g399852g13w95.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+`"@`P$1``(1`0,1`?_$`*0```("`P`#`0``````
M``````8(!PD`!`4!`@H#`0$``P$!`0$`````````````!@<("04"`Q````8!
M`@4"!0,#`0D``````0(#!`4&!Q$(`!(3%!4A%C$B(Q<)03(D46$E0X%"4C,T
M-28V&!$``0,#`P($`@@#"0```````0`"`Q$$!2$2!C$'02(3"%%A<:$R<B,4
M%0G!4D.!D=%B@M)3%AC_V@`,`P$``A$#$0`_`/LVSCN`FZO8EJ12R((23-)`
M966<MP<JH.'2)'"35DW5`4-2-E2',H<IP^8``/0>.4?O&][?<#@O<23LGV1A
MBCY):QQ_G+V2(3/CDFC;*R&WBD_"&V)['OED:\5<&M;4.*NG@?;O'Y7&-SV=
M+G6KR?3C!V@AI(+G$:ZD$``CI4J+8C*F:I,Y$PMRYE#@)BI)0T'J8"E$XB'-
M&>H<I1'_`&<5_P!ON>^\_DD<<N8YG<-D>*^G'C\8-*5IN-GK]7BI+?\`&N"6
M@)%DW:/$R2_[T2FO>:.FU.6UNM'B:JB`A$0@_(@HHFJ<VL9H4J8I&$PC\`#4
M>+JFR/NB_+1OAY??;I6%S3^3QO1I(<36RII0D^`&I7CC$<)WN#K-E&$`_B2^
M(!']3YA!3_-&9XI3J^ZP<D14YA16AX82*%*.HIGZ<>F8Q?ZZ&`=!^(<9BY[W
MJ][7`Y/U3'\K=D+&%VYT4N/QPW`&M#LM6ES2.H:YIIT*D=GP[@E\WTS9['.'
M422Z?,5>?K!3;X2RX3*<([,\:I,;!#*)(2C=`3=LN58HBB]:E4U.F17E$#$$
M1Y#?J("''0GV<>Z/_P!)\,NWYRUCL>>8>5D5[%'7T9`\$QW$(<2YK7[2'QDN
M]-^@<012H>=\-/$[]@MWF3&S@F,G[0IU:ZFA(\#I4>"FWC8R@B&;G;H&@U.Q
MW:SODHVO56&D)V8>K"`$;L(ULHY7,'_$<2)Z%*'J8P@`>H\$2T[.MV4#NRHD
M[9V,8E79RMV-W$2]=!YWBK5@N8[BO2(JB4@B61CPT-H&@+)*`'RZ<$3><$29
M;E=S.2-ML%+7V6PE'6O&<5),F2UDB<GMF,RDC(KIM6;EW6GU1$R0J.503$J;
MI8"B(:FT'4"+@X0W39HW!48F2*#MTAV]1>N'[:$=V7,C.,?3"D<N+9R*3%K1
M9'MD2N2F(!U#@`F(;]`U$BU*[OSJC',B>`LXT2<P?DAXJR1B/*R\;9J?-JR6
MH1@1]HC4V8`G)G`2-U%6R:9U`Y!,4WIP1/FHHFBFHLLH1))(AE%55#%(FFF0
MHF.HH<P@4A"%`1$1$```X(D7D-\]7M.07V*=NE#L6X2Z1)CEG)"N/6,#CRNE
M(H"!EYB]29%V8-TW(\G,@BL50P""9CCH`D4IFEMWAV?D$J7@)!7DZOMY>[7E
M:0`.0P]J,PE4TXON>?E+S<G2^(Z_IP11IBC=?D"Q9[/MXR]@QUBFV'J\O:8F
M<);$;#7K*SB5V:*@P*Z<,S2>HJ%=";F*N8Y!3,4Y"B`\$3Q\$2N[N-S<#M6Q
M2XR!),D9N:>R;*#JM9.[!FI.2KDPJKD!70QB(,8]%5=0P`(@!`#XCP13+B[(
MD!EG'E0R/6%RN(.X03&:9&*<#BCW*0=PT4,`!JLR=%.B?T#YB#P1'O!%5GF)
M0I\]7D@@F(E>PY/G433#3V]$'Y1.<2`0!_7UUTXXD=S^-X_(>\;F60N&,?<&
M\LFC<0*`8ZS)H212OTA:EXFY[.W]A2M/3D.@)_K2#P4JIRL92:>G/"@@[?'D
M&#6.16>1SY*.?*G!4KT'48Y[A%$I2"`MUB:*?#7X\;'ES>&[9\0L\EZ44E]<
MW<4-N'R1/9%(?-ZF^-^X"@/X3A1YTKU4+-K=9S+.L]SFP-C<YY#7-+VC3;1X
MH3_F!T^"DZ`G8^1@E'\G)11C=%P4S!-J@U^@^6[AXBW50`%6_7-KJ.HCH(A\
M.+KP.5L,AA/SM_/;/K&ZK`QK!MD.Y[6ENK=QK4@G0T47O[.XM[[T;>.0:CS$
MDZM%&DUT-%$N4HF-;D([9=$4EVR"Z*?>Q31)JW<(D7233CBNE7P&3(H',940
M,<=1'^O%%=Y^,8>?'NN(&L,3X0Y@WPL:QKF[F@1[B^H!U+]7&I*EG%KVY<_T
MI:U#B"=KR20:$EU`W6F@'1=;9XH0\OD$""&@)10_$!]1.L`CZ?#BK/V_,+9X
M;N%SAED`V.6.T<0/`U?7HOOO%N-ACB[K63^">WCJ:J'5:&ZK)=2REG[&.S][
M;:["U!D#3,.XI>9G(Z(:+4Z`=-W-/QTLL^=-B*N+E/=!9R@0P+$9$34#4AC<
M$5;E+R=6=C/Y+9"M1%MK\G@;/CE`B#J#FH^4AH1O<)!12+(NK'+N&K):KVL#
MH`0`YP8JI@`Z&'@B^E(!`0`0'4!]0$/4!`?@(#P15L_EI?\`C-C^3'?/R<DS
M1B\WP_?:XPNFOIIKKP1+-L`WM;<\)[*L=H9;OSJHNV$G;$%CO:;>7,<NNZLL
MDX:MV4ZPKCN!>++I*@!2E="8#ZE$`$-."($FL5W'\F.YJD[A,?M34S:_2@@F
M$9D":58I62]K5:;/*R)8*LMG3B29`K)(E0(9^5L9%+4XE$3%+P1,7^8G/%CP
MSMJAJU57[N(=Y5M'M:4EFJBJ3A.M1S`SZ7CTW2?*9!26,=%,X\P"=`%2>H&'
M@BG#\9F+JYCO:'BV6B6[<TSDN%0R!:)<B?*YDWLV*BL>BJH8.?H1,4*3=,FO
M(`E.</4YA$B?_@B%Y:E56<L-9MDM!LGUDIHR@UB95*<'T,$TW2:2I&JI#D^F
M^;HD*H4P&*/*`Z:^O!$3B(%`3&$"E*`B8PB````&HB(CZ``!P14U/7^)M\V2
MMP=BO60:5&8MH<#9\`X/;S%J@8U5Q<'""8WK*;-N[?(N`Z,F1%BQ7Y#D4;$,
M=(VHCP11'^'W<4ZBK)D_9M>9EDZG*7+SDY15D':+IJ^;Q[\S.UL(IPDJL1TR
MZ_3?MQ*<2@@L.GZ\$5^7!%2_N7G7->W$7H5TU$TEUH-TW!4IBE61-7HI(JZ>
MNG.B95$Y.8/3F*(?IQP#]S/,;S@GO`Y2^]8^.RNIK&1A<"&N:+"U9O;\6ES'
M-J--S2*Z%;,[<8^/)=N;`1D%[6RM-.H/K2&A^="#3X$(MJ&7J].0PU2UII/8
M=^9$7B*@E9LHQ%L/6,\8),@0.K-:$$$7!S?3.8/0VH\:8XCW;X1S_BW_`%'F
M38[C"7!#G>81-@$?F$T/I[7"Y'2.4FK7$"C@36.Y;BF3QM]^JXHEEVP':?M.
M>7:;7%U1Z?\`,T#4#PT1-&R^*(8C!ZD_GG@/6THZ:1DQ,%<1K%TT?*I1;22!
ML@V7=HO46^B@&.7E%0!_:`\3'!3]KN-16]PS)Y6ZMI(Y7Q07-PQT3'1R.;"R
M8QLC?(UX91]7-U<"?*"O+NK;E%ZY\3HK=CF.8'/CC(>X.:"]S*EP:6DZ4!Z'
MQ47Y-S<2P'.)%?I&+Z-5^BY,Q,7Y>BR?B0')F1?],AA$2%T+\V@#Q3?>[W#X
M^\M)&ME`;MIZ9VN+#0@-9)3?L_E:3Y10&M*F4<7X0^S(W#S5^T*C=\W-^SN^
M)`U.NG1,'L*<.Y-;),J9%3L^I#-".1UZ1E^5PJ*("(^JA4_4=/AJ&NFO$O\`
MVS[W)\AS?-.3SQO_`$][K2)KR/+O`>[8#XNVZGK32IZ*&]^8H;2+&6@</6I(
M[;XTT%?HJF1W-[GL3;4L37'*^4;3"Q+.LPSIY'03J69M)JTS/04&(KD$Q44%
MV\D9AX!4B`FF?IE$RA@`A#"'6A9S2&?C@PQCG->$GVYS-L-C7,&7-SMFD\N6
M-Q+QM?N1*9"R*HLZE18T)!)^I$M:]"()@HWT(9%=4R0ZE3)H10C^9S:CAV/V
MFRF5L;UO'>+[OAB39VX/;C*NTQW8:TY6)'SD8!&"3%:2?-RJD=,R%*=3N$-"
MZ:CP1,;^*G?S1-U^W"G1=DO-:1SA0&:-.O-8?3,>SGY3Q)2M8>ULHQ=1%R\C
MYN.*F)E$@5`K@IP.8##IP1#'YO,@U2M["LE1+RT0#*PR=CH+:*@UYB/1F9%=
M*U1SMPDRC5%P>.#H,VZBI^0@\J9!$=`X(@?\2@X6W$?C3JN'+I(5"Z-)%UD&
MMW2DKRT>XEV"CRT2;YH5Q'E7"1CGY6KM%TU6*4IRB)3D-J'!%7%`97RG^$#=
MX\QAD=2=N>SS,$B:4A)L4U%>2*,N5$+'%)\P-DKM3R*D1F&91+W[4"K$]1)H
M17.;U\/X]_)3M.5BL$9-HUGL[)5AD7%<]#V&-DHI[+,V:Y30,NLR6<+Q;2=8
M/#H*"H0AVSH$C*@!2'#@B33\76_2,Q3#,]AN\LCG`F<<7.WD%0ULEB2NPUWK
MIW:CEE"LIY^*,0K+Q)G(IM#%6%O(,NB*!SG*)3$5_I'[%1F613>M%(\R/<%?
M$<HF9F0TUZY713B@*.GKS<W+I^O!%6GFO\DN,X+<5A7:1@:=J&5LY9-R!$Q%
MI;L9#S%9QU2FB;B7MCZ;DH1X"7NGP<>L#-F50W24^=P!2@4IR(4_*%O;K.$<
M5,L*8\O]60W!;A9IABVG-@L4<BXI$59W2,18+[.KD<_X!I%,7@I-5W`IAW:I
M3EYBHJ:$328=V;;8:+BZB4MEBS%-W3JU:BX9Q;I.G5:>D;'(-FQ!DYM]*.63
MU9PYE7YU'!@%0P$ZG*70H`'!%0!^5V*@-@>[[;KNVP7[5K;25E"M[#C^LKQ$
M6D65JA$_,(EKK`2D:1ULJCQ9!90R)4NZ*0?W!P1?2I@O<'B/<;C^M9&Q+>:W
M;X.R1#63(G#R[-W(1BJR)#NXN8CDU>^BY.-7,*2Z*Z::A#E]0T$!$BU\Q;>L
M<9M;MQMK!RVF6*)D(^R0RY64RU1,(G!N=4R2R#QH"@\W26(<H#KR\HB(\9Z[
MX^V/M3W_`+>)_-K22/.V["R&^MG"*YC::G87%KFRQ@DD,E8X`DENTDDS?B'<
M'D?"I'#$R-=9O=5\,@W1N/Q`J"UU--S2#\:T2LE_'54$CB9OE.[I%UU*46$$
M<0#]`,8&Q`,(?U``XRK9?MI\.QCJ8WEV?BAKHTQ6KJ#X'R@?W`?0K-=[A,M(
M/Q<79$_>E'\2M@?Q[5PP`4V6KN8H>@%&.@]`#]0#Z/H`\>U)^WIAI&>F[F>>
MVT_X;73Z/*OR'?N^!J,395^_+_BO+#\==`3>)+RV1+S*-"&`RC--*$CQ6#4!
M$IG2;)=4A1`/]T`'^_'CP?ME]MI[]EUR'DG(+ZV::NCI;Q;OD7B-Y`^Z`?@5
M]3>X3/\`HF.SQ]C%*>CJR.I_I+@#_:G?HU#JF-ZZSJU-B$(:&9`(D02$ZBJZ
MY]!6=O'*QCKNW:YO4YSF$1^`:```&]>WG;?A?:KB\'#N!V,5A@;>I#&U+GO/
MVI)9'$ODD>=7/>23T%&@`4KG,[E>1Y%^4S$SIKQ_B=`!X-:T:-:/``?7JEMW
M(XLV<Q#*=SON%PCC*X.FS>*C):W6+%\1>;"HW1_@PS(57$3(O00(8Q44M1*F
M4QBE$0U#B<+R%(V&<$X!QNF6[X@PC1,2R5Q@V)Y(U9I$%3II>/=$;OTH^;1A
M6R)>LB<I!43,8W*H3XCIP1"EQQ=M6SWE.8A<D8:HF2LB8_A8PKF2OV,&\XG'
MQ$F*J[)M%3]@AEHQV4#+F,9-NJ<R8G'4`]>"+$MCNS9!XPD6VUK`;61BGC>1
MC'[3%5,:/8]^U4*LV=LW;:(2<-W""I`,4Q#`("'!%T[7M#VFV^S2EUN^WC"5
MFMMA<D-+66T8\J<Q-2KH0Y4^YDI6-<.G"Q@#0`YM1TX(O%>V<[3J;98:[5/;
M=A6L6VLNR24#9*YC6JQ$[$O4/G2<Q\A&1;=XBN0?VB4VNOPX(N:B?;=O,8ST
M-:,9U_*T!BVYJQ8AD['K"3AV-R:(*H2!J^A9F3@X/HT@B@X5(DF)#&Y-1X(C
M''VV#;EB6R#<,78,Q3CNTF8.8L]@I5$KE9E5(YX=([IDH]AX]HLHW7.@03%,
M(@/*'!$290PCAS-D2$'F#%M`R=$%*)4V%ZJ4'9T$2B(F$&X2[)T9M\PB/TQ*
M.OKP1+RA^.C92V0*S0P#5TXTAA$L,65MO@0((B/0\"-B&&%IZZ='H=(`].73
MTX(ICQMMAVXX==-W^*<$8CQW(-"*$:R5.Q]5H"2;E6(9-8$9&.C$'J8K)F$#
MB"FIP$===1X(@Q38YLU66<N'&UG`3IR]77<O'3O%5,=NG3ARH=9PLY<N(=5=
M=5950QC"8PB(CP13?CW&>/<35Q.GXQI=9H-51=N7R-=J4.R@H9%X\$@NG*4?
M'HH-DU7`IEYA`H:Z!P10Y*;+-HD[,R]CG-L^#9J?GGJTC-34QC*HRDI)OG!S
M*KNGKY]%+N5UE5#B8PF-ZB.O!%WZ'M7VU8LM*5WQI@;$N/[>BS<1Z=DIM"K=
M;F2L70:.&@OXB/:+F06#]Q1$0'@BGS@BS@BS@BS@BS@BJ<WCY`;9.S[4<!#?
M8C'E&PLSA,VY@G99-L]?24@NJ8V/JM5JRY$RMMG%SI*.$6Z23E,5A`%$5-"I
MG(INQ;>,D8CVPY4RWN`O,Y&(IRUVNM)>9'C6#ZW5&@.2((TB&M,3$IP2#VQN
MEB`J#$G1,55V1O\`()>4"(/P#FC(]8V<9,W+9&LD_E><[>Y9$B:QV:1CP,,Q
M9@O!U%B:,C8YK(&2;=-1XHSZC<BACID-SI*<$05B'*^<;/F3;[`-<AN<@V*R
M5V7R9N:90XQSG%N.:;88,%:)3(=%BV.C#6)*170.@91P=^[2!4ZHF+H`$7,W
M(WN`R1ND?TJSY6D:OB+:_04<KW1&MRK&OSI<JRJ*[>B0L(^1!Q)3DX0@@Y1;
MD34$J_\`'!/G4]2*2X#.&8\1;`8K)V;@D)#-TI!JQE<BI-LW;6.8LUQG'$3C
M:*DF35!L4LTY;OFAUR],%4R@(JASE/P10+@*JY4I4MMHQGCG-A[C9FEKMMLW
M-0],=5^0Q]58HQ7:EC87)PU9.G+Z^O[:[(T$5W:;@ZZ1Q22(FF)C$4W[A-]U
M*HE@RU74KDWJ\-A!G'HW5Q%E92&0[C<9QOS1=)I$2^0=-82+9G62\G//$%$$
M5%`21+S`)Q(B;%.0[91ME%CS7E3+<K(V=W`V:^2MFE62$FG55%04\;4ZM'+M
M8V.E/&E33:H"D15L[?',9/J)F*'!%Z[1L=[DK)0\<92SKG+(C::>R#RXM\:M
MBU8(M:JV!(7$3`7ETK7!DI%T5JJ18"H*-!:>A"Z&YP`B6[,VX[*A\PY8O5:S
M#,P>WC"(.<>R"5<AX7KY)S#/$(C"8KQVW=MI-:;M+5\LDB[E#"LFW$3B@B4P
M"4I%Q\'W[<F^SSA'!F0,\V)W=ZHS/D/-\&@G%/VD/#V!-67J.)YD\;#KO9^S
M+QZG4D9%=1!FP;"0B9NJ4#*$3,[@M\--H%RR91R6UO4XS"M>C9S)DJT2:RE\
MFI6=9=_!T3'5==(N4"NG+)1-9_,NDE&C!-4A0+SCSD(I8V0REWM6$V>0<@WB
M<N5AR!,25D!O*KE<,JE$.5A&#JL0NA'QS!\G&19D@<NVI!;N70G$HZ@(`1.#
MP19P19P19P19P19P1`<A]L?>,=Y7V']P.F3Q/D/;_O'HZ?3\=W/^;Z>G[>EZ
M?TX(N_9?;/A'WO'P7MSD3\E[E\?X3I]5/I=]Y3^#R=?EY>IZ<^FGKIP1;:/B
M/$I]OXWP7CR]+H]KXGQ7;_+T^3^'X_M?AI]/I_VX(N!3?M_V3O[>^SO'=V/?
M^S?"]EW_`"%YN[\)]#N^GIKS_/RZ?IP1*1MS_P#E#SN7?9G+]P/OG9ON#]W>
MU^X/W/Z4;WGBO<G^2\7VW0['LOX_+KT_FYN")U)3PO*T\UXOD[YOV'E.TY?)
M<P]IVG=^G?<__+Y/J:_MX(N-5?8G-->R?:7-Y9Q[B]J^'YO.<Y^Z\UXCU\MS
M\W4Z_P!;777@BX$K]G.YLWG/MGWG(S]Y>5]K=ST^LCX_W-W?U>3N.GT>Z].?
MEY?73@B,'WMOPI/)>#]N]%IT^^[#PO;ZI=AR=Q_!Z.O)T=/E_;R_IP1=LO+R
MARZ<N@<O+IR\NGIIIZ::<$0E_P"!]DW_`/4?'>=_B_\`9NR]S]<W_3_Z'G>Z
MU_;_`".IK^O!%^T=[+]R3?B?:_N_I-?<?CO$^Y.AR)]EYOMO\GTNGR]+K^G+
MIR^FG!$/RWVA\A8_._;?RWCT?=WEO;'D/%?2[?W'WG\GQ_[.3N?I_MT_3@B/
H6'8]DT\9VGCNV1[#L.CV7:=,O;]IV_T.VZ6G)R?+RZ:>G!%M\$7_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
